Browse > Article

Evaluation of Usefulness of Radio-iodine SPECT/CT in Differentiated Thyroid Cancer  

Lee, Jeong-Won (Hospital and Research Institute, National Cancer Center)
Lee, Ho-Young (Hospital and Research Institute, National Cancer Center)
Oh, So-Won (Hospital and Research Institute, National Cancer Center)
Kim, Seok-Ki (Hospital and Research Institute, National Cancer Center)
Jeong, Ki-Wook (Hospital and Research Institute, National Cancer Center)
Kim, Seon-Wook (Hospital and Research Institute, National Cancer Center)
Kang, Keon-Wook (Hospital and Research Institute, National Cancer Center)
Publication Information
Nuclear Medicine and Molecular Imaging / v.41, no.5, 2007 , pp. 350-358 More about this Journal
Abstract
Purpose: Localizing and differentiating a metastatic lesion of differentiated thyroid cancer (DTC) by using radio iodine whole body scan could be difficult because a whole body scan (WBS) lacks anatomic information. This study was performed to evaluate the usefulness of radio-iodine SPECT/CT for differentiating equivocal lesions. Materials & Methods: Among 253 patients with DTC who had undergone radio-iodine scan between February and July 2006, 26 patients were enrolled (M:F = 8:18, Age $50.7{\pm}12.5$ years) in this study. The patients had abnormal uptakes in the WBSs that necessitated precise anatomical localization for differentiating between a metastatic lesion and a false-positive lesion. SPECT/CT was performed for the region with abnormal uptake in the WBS. WBS and SPECT/CT were evaluated visually. Metastases were diagnosed based on the results of the radio-iodine scan along with the results of other radiological examinations and serological tests. Results: Based on the WBS images, 13 were suspected with cervical lymph node (LN) metastases in 16 patients with abnormal neck uptake, and in the 11 patients with abnormal extra-cervical uptakes, extra-cervical metastases were doubtful in all. After SPECT/CT was performed, the diagnostic results were altered for 16 patients (62%). SPECT/CT revealed that only 5 patients had cervical LN metastases, while 3 patients had extra-cervical (mediastinal) LN metastases. Overall, there was a 58% (15/26) change in diagnoses and plans for treatment due to SPECT/CT. Among 8 patients suspected with metastases on SPECT/CT, 6 patients underwent another radio-iodine therapy. In 96% (24/25) of the patients, the results of SPECT/CT corresponded with those of further radiological examinations and with other clinical information. Conclusion: Radio-iodine SPECT/CT images permitted the differentiation of abnormal radio-iodine uptake and improved anatomical interpretation in DTC.
Keywords
thyroid cancer; iodine radioisotope; SPECT/CT;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Unal S, Menda Y, Adalet I. Boztepe H, Ozbey N, Alagol F, et al. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases. J Nucl Med 1998;39:1897-902
2 Intenzo CM, Jabbour S, Dam HQ, Capuzzi DM. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med 2005;35:257-65   DOI   ScienceOn
3 Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M et al. Impact of I-131 SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31:1435-42
4 Townsend DW, Cherry SR. Combining anatomy and function: the path to true image fusion. Eur Radiol 2001;31:191-205
5 Yamamoto Y, Nishiyama Y, Monden T, Matsumura Y, Satoh K, Ohkawa M. Clinical usefulness of fusion of I-131 SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med 2003;44:1905-10
6 Bryan RH, Furio P, Christoph R, Martin S, Paul WL, Steven IS, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85   DOI
7 Amthauer H, Denecke T, Rohlfing T, Ruf J, Bohmig M, Gutberlet M, et al. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 2005; 15: 1456-62   DOI
8 Ministry of health and welfare. 2002 Annual report of the Korea central cancer registry (2003)
9 Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasm. Eur J Nucl Med Mol Imaging 2003;30:835-43   DOI   ScienceOn
10 Anderson GS, Fish S, Nakhoda K, Zhuang H, Alavi A, Madel SJ. Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report. Clin Nucl Med 2003; 28(2): 93-6   DOI
11 Weber T, Schilling T, Buchler MW. Thyroid carcinoma. Curr Opin Oncol 2006;18:30-5
12 Mitchell G, Pratt BE, Vini L, McCready VR, Harmer CL. False positive I-131 whole body scans in thyroid cancer. Br J Radiol 2000;73:627-35   DOI
13 Even-sapir E, Keidar Z, Sachs J, Engel A, Bettman L, Gaitini D, et al. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasm. J Nucl Med 2001;42:998-1004
14 Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63   DOI
15 Sherman S. Thyroid carcinoma. Lancet 2003;361:501-11   DOI   ScienceOn
16 Ruf J, Lehmkuhl L, Bertram H, Sandrock D, Amthauer H, Humplik B, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 2004;25:1177-82   DOI   ScienceOn
17 Lupoli GA, Fonderico F, Colarusso S, Panico A, Cavallo A, Micco L et al. Current management of differentiated thyroid carcinoma. Med Sci Monit 2005;11:368-73
18 Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, et al. Artifacts, anatomical and physiologic variants, and unrelated disease that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000;30:115-32   DOI   ScienceOn
19 Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systemic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76   DOI
20 Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma. J Clin Endocrinol Metab 2002;87:3242-47   DOI
21 Edwa rds BK, Howe HL, Ries, LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973.1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002:94; 2766-92   DOI   ScienceOn
22 Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26(1): 6-9   DOI   ScienceOn